

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM506163

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Assignment Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Pharm-Olam International, LLC		12/29/2018	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Pharm-Olam, LLC		
Street Address:	450 N Sam Houston Pkwy E, Suite 250		
City:	Houston		
State/Country:	TEXAS		
Postal Code:	77060		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	2655571	PHARM-OLAM	
Registration Number:	5258879	PHARM-OLAM HELPING CREATE A HEALTHIER WO	
Registration Number:	4854480	POI	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-819-2655		
Email:	iprecordations@whitecase.com		
Correspondent Name:	Peter Giovine/White & Case LLP		
Address Line 1:	1221 Avenue of the Americas		
Address Line 4:	New York, NEW YORK 10020		
ATTORNEY DOCKET NUMBER:	1136321-0104-BC15		
NAME OF SUBMITTER:	Peter Giovine		
SIGNATURE:	/Peter Giovine/		
DATE SIGNED:	01/16/2019		
Total Attachments: 17			
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page1.tif			
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page2.tif			

CH \$90.00 2655571

source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page3.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page4.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page5.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page6.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page7.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page8.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page9.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page10.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page11.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page12.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page13.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page14.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page15.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page16.tif
source=Pharm-Olam, LLC - IP Assignment Agreement [EXECUTED]#page17.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (“**IP Assignment Agreement**”) is made and entered into effective as of December 29, 2018 (“**Effective Date**”), by and between Pharm-Olam International, LLC, a Delaware limited liability company (“**Assignor**”), and Pharm-Olam, LLC, a Delaware limited liability company (“**Assignee**”).

WHEREAS, Assignor and Assignee are affiliates with Pharm-Olam Holdings, LLC, a Delaware limited liability company (“**Pharm-Olam Holdings**”);

WHEREAS, prior to the Effective Date, Pharm-Olam Holdings and Assignee entered into that certain Contribution Agreement, pursuant to which Pharm-Olam Holdings contributed all of its membership interests of Assignor to Assignee;

WHEREAS, contemporaneously herewith, the parties hereto have entered into that certain Distribution Agreement (the “**Distribution Agreement**”), pursuant to which Assignor distributes and assigns to Assignee, and Assignee assumes and accepts from Assignor, all of Assignor’s right, title and interest in and to, and obligations under, the Pharm-Olam Assets (as such term is defined in the Distribution Agreement), including the Transferred IP (as defined herein);

WHEREAS, Assignor is the owner of all right, title, and interest in and to the Transferred IP (as defined below); and

WHEREAS, Assignor desires to further confirm the assignment to Assignee, and receipt by Assignee, all of Assignor’s rights, title and interest in and to the Transferred IP pursuant to the terms and conditions set forth herein and in the Distribution Agreement.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. Defined Terms. Capitalized terms used but not defined in this IP Assignment Agreement shall have the meanings provided in the Distribution Agreement.
 - a) “**Intellectual Property**” means any and all proprietary and intellectual property rights, title, and interests in, to or under any of the following, whether protected, created or arising under the laws of the United States or any other jurisdiction or under any international convention: (i) all patents, patent applications, patent disclosures and inventions (whether or not patentable and whether or not reduced to practice), including all continuations, divisionals, continuations-in-part, continued prosecution applications, and provisionals and patents issuing thereon, and all reissues, reexaminations, substitutions, renewals and extensions thereof; (ii) all trademarks, service marks, trade names, certification marks, slogans, corporate names, trade dress, logos and other source or business identifiers and indicia of origin, together with the goodwill associated with any of the foregoing, and all applications, registrations, renewals and extensions thereof; (iii) all internet domain names; (iv) all copyrights and works of authorship (including in software, data, databases and collections of data), design rights, and moral and economic rights, and all registrations, applications, renewals, extensions and reversions thereof;

(v) all trade secrets, know-how, confidential information, and proprietary data and information (including compilations of data (whether or not copyrighted or copyrightable), ideas, formulae, compositions, blends, processes, know-how, manufacturing and production processes and techniques, research and development information, drawings, specifications, designs, plans, improvements, proposals, technical data, financial and accounting data, business and marketing plans, and customer and supplier lists and related information); (vi) all software or computer programs; (vii) all rights of privacy and publicity and in social media usernames and accounts; (viii) all other intellectual property or proprietary rights, or other intangible assets, of every kind and nature however denominated; and (ix) all registrations, renewals, recordations and applications of or for any of the foregoing.

- b) “**Transferred IP**” means and includes all right, title and interest in and to any and all Intellectual Property owned or controlled by Assignor throughout the world immediately prior to the Effective Date. The Transferred IP includes without limitation:
- i. the patents and patent applications set forth on Schedule A hereto and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, renewals thereof (the “**Patents**”);
 - ii. the trademark registrations and applications set forth on Schedule A hereto and all issuances, extensions and renewals thereof (the “**Trademarks**”), together with all goodwill of the business connected with the Trademarks;
 - iii. the copyright registrations and applications set forth on Schedule A hereto and all issuances, extensions and renewals thereof (the “**Copyrights**”), together with all goodwill of the business connected with the Copyrights;
 - iv. the domain name registrations and applications set forth on Schedule A hereto (the “**Domain Names**”), together with the goodwill of the business connected with the Domain Names;
 - v. all trade secrets, know-how, and all other related Intellectual Property owned or controlled by Assignor throughout the world;
 - vi. all rights of any kind whatsoever of Assignor accruing under any of the foregoing provided by applicable law;
 - vii. any and all royalties, fees, damages, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and
 - viii. any and all claims and causes of action, with respect to any of the foregoing, whether accruing before, on and/or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Assignment. Assignor hereby absolutely, irrevocably and unconditionally conveys, assigns, transfers and agrees to assign and deliver to Assignee and its successors and assigns, and Assignee (on behalf of itself and its successors and assigns) hereby accepts and receives, all of Assignor's entire worldwide right, title and interest in and to the Transferred IP, as fully and entirely as the same would have been held and enjoyed by Assignor had this IP Assignment Agreement not been made.

3. Recordation and Further Actions. Assignor hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office, the U.S. Copyright Office and all similar or corresponding foreign governmental authorities, and each applicable domain name registrar to record and register this IP Assignment Agreement upon request by Assignee. Following the date hereof, upon the reasonable request and at the cost and expense, if any, of Assignee, Assignor shall use commercially reasonable efforts to execute, acknowledge and deliver all such additional instruments and other documents and take, or cause to be taken, such further actions as may be reasonably required or necessary to effect, evidence or perfect the assignment of the Transferred IP to the Assignee.

4. Successors and Assigns. This IP Assignment Agreement will bind and inure to the benefit of Assignor and Assignees and their respective successors and permitted assigns.

5. Counterparts. This IP Assignment Agreement may be executed in two or more counterparts, each of which shall be deemed an original copy of this IP Assignment Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. This IP Assignment Agreement, and any amendments hereto or thereto, to the extent signed and delivered by facsimile, by electronic mail in "portable document format" (".pdf") form, or any other electronic transmission, shall be treated in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person.

6. Severability. If any term or other provision of this IP Assignment Agreement is adjudicated by a court of competent jurisdiction to be invalid, illegal, or incapable of being enforced by any law or public policy, that provision will be deemed separable from the remaining provisions of this IP Assignment Agreement, and will not affect the validity or interpretation of the other provisions of this IP Assignment Agreement, and all other terms and provisions of this IP Assignment Agreement shall nevertheless remain in full force and effect. Upon any such adjudication that any term or provision hereof is invalid, illegal, or incapable of being enforced, this IP Assignment Agreement shall be reformed, construed and enforced so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this IP Assignment Agreement are consummated as originally contemplated to the greatest extent possible.


7. Governing Law. This IP Assignment Agreement and all claims or causes of action (whether in contract or tort or otherwise) that may be based upon, arise out of or relate to this IP Assignment Agreement or the negotiation, execution or performance of this IP Assignment Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to conflict-of-law principles that might require the applicable of the laws of any other jurisdiction.

[Signature Page Follows]

IN WITNESS WHEREOF, the duly authorized representative of Assignor has duly executed and delivered this IP Assignment Agreement as of the date first written above.

Assignor:

PHARM-OLAM INTERNATIONAL, LLC


By: 

Name: *Robert K. Reisdorf*
Its: Vice President, Assistant Secretary and Assistant
Treasurer

AGREED TO AND ACCEPTED:

Assignee:

PHARM-OLAM, LLC

By: 

Name: *Robert K. Reisdorf*
Its: Vice President, Assistant Secretary and Assistant
Treasurer

[Signature Page to Intellectual Property Assignment Agreement]

Schedule A

Patents: None.

Trademarks

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
US	"Pharm-Olam"	2655571	December 3, 2002	76117037	August 25, 2000
US International Madrid/WIPO	"Pharm-Olam"	1263707	March 4, 2015		
US	"Pharm-Olam Helping Create A Healthier World"	5258879	August 8, 2017	87062613	June 7, 2016
US	"POI"	4854480	November 17, 2015	86553681	March 4, 2015
UK	"Pharm-Olam"	1263707- WIPO	December 8, 2015	1263707- WIPO	April 3, 2015
UK	"POI"	1257887	March 9, 2015	3395978	March 20, 2015
Argentina	"Pharm-Olam"	2784354	May 2, 2016	3395978	March 20, 2015
Argentina	"POI"	2784356	May 2, 2016	3395980	March 20, 2016
Algeria	"Pharm-Olam"	93215	June 7, 2016	150930	March 8, 2015
Algeria	"POI"	93214	June 7, 2016	150929	March 8, 2015
Austria	"Pharm-Olam"	1263707	March 4, 2015		
Austria	"POI"	1257887	March 9, 2015		

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Bangladesh	"Pharm-Olam"			183773	March 4, 2015
Bangladesh	"Pharm-Olam"			183774	March 4, 2015
Bangladesh	"POI"			183775	March 4, 2015
Bangladesh	"POI"			183776	March 4, 2015
Belarus	"Pharm-Olam"	1263707	March 4, 2015		
Belarus	"POI"	1257887	March 9, 2015		
Benelux	"Pharm-Olam"	1263707	March 4, 2015		
Benelux	"POI"	1257887	March 9, 2015		
Bosnia Herzegovina	"Pharm-Olam"	1263707	March 4, 2015		
Bosnia Herzegovina	"POI"	1257887	March 9, 2015		
Brazil	"Pharm-Olam"			909154805	March 24, 2015
Brazil	"Pharm-Olam"	909154724	September 19, 2017	909154724	March 24, 2015
Brazil	"POI"	909154937	August 29, 2017	909154937	March 24, 2015
Brazil	"POI"	909155020	August 29, 2017	909155020	March 24, 2015
Bulgaria	"Pharm-Olam"	1263707	March 4, 2015		
Bulgaria	"POI"	1257887	March 9, 2015		
Cambodia	"Pharm-Olam"	62519	June 26, 2015	62519/2015	March 5, 2015
Cambodia	"Pharm-Olam"	62520	June 26, 2015	62520/2016	March 5, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Cambodia	“POI”	62521	June 26, 2015	218317/2015	March 5, 2015
Cambodia	“POI”	62522	June 26, 2015	62522/2015	March 5, 2015
Canada	“Pharm-Olam”	TMA932419	March 22, 2016	1717433	March 2, 2015
Canada	“POI”	TMA932062	March 18, 2016	1717437	March 2, 2015
Chile	“Pharm-Olam”	1191939	January 8, 2016	1149832	April 8, 2015
Chile	“Pharm-Olam”	1176436	August 24, 2015	1149835	April 8, 2015
Chile	“POI”	1149830	November 19, 2015	1149830	April 8, 2015
Chile	“POI”	1149831	August 19, 2015	1149831	April 8, 2015
China	“Pharm-Olam	1263707	March 4, 2015		
China	“POI		Refusal		
Costa Rica	“Pharm-Olam”	244733	July 10, 2015	2015-002255	March 6, 2015
Costa Rica	“POI”	244732	July 10, 2015	2015-002254	March 6, 2015
Croatia	“Pharm-Olam”	1263707	March 4, 2015		
Croatia	“POI”	1257887	March 9, 2015		
Czech Republic	“Pharm-Olam”	1263707	March 4, 2015		
Czech Republic	“POI”	1257887	March 9, 2015		
Dominican Republic	“Pharm-Olam”	223877	August 17, 2015	2015-9489	March 26, 2015
Dominican Republic	“POI”	223876	August 17, 2015	2015-9490	March 26, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Ecuador	"Pharm-Olam"	IEPI_2017_TI_6930	July 6, 2017	IEPI-2015-12130	March 27, 2015
Ecuador	"Pharm-Olam"			IEPI-2015-12105	March 27, 2015
Ecuador	"POI"	IEPI_2018_TI_880	December 7, 2016	IEPI-2015-12099	March 27, 2015
Ecuador	"POI"			IEPI-2015-12100	March 27, 2015
El Salvador	"Pharm-Olam"	77261	June 8, 2016	20150215236	March 20, 2015
El Salvador	"Pharm-Olam"	77267	June 8, 2016	20150215236	March 20, 2015
El Salvador	"POI"	72177	January 26, 2016	20150215239	March 20, 2015
Estonia	"Pharm-Olam"	1263707	March 4, 2015		
Estonia	"POI"	1257887	March 9, 2015		
France	"Pharm-Olam"	1263707	March 4, 2015		
France	"POI"	1257887	March 9, 2015		
Georgia	"Pharm-Olam"	1263707	March 4, 2015		
Georgia	"POI"	1257887	March 9, 2015		
Germany	"Pharm-Olam"	1263707	March 4, 2015		
Germany	"POI"	1257887	March 9, 2015		
Guatemala	"Pharm-Olam"	216896	August 21, 2016	2015-2699	March 20, 2015
Guatemala	"Pharm-Olam"	216985	August 21, 2016	2015-2700	March 20, 2015
Guatemala	"POI"	217064	August 21, 2016	2015-2701	March 20, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Guatemala	“POI”	216947	August 21, 2016	2015-2702	March 20, 2015
Honduras	“Pharm-Olam”	21947	November 26, 2015	11880-15	March 20, 2015
Honduras	“Pharm-Olam”	21576	August 20, 2015	11881-15	March 20, 2015
Honduras	“POI”	21573	August 20, 2015	12055-15	March 23, 2015
Honduras	“POI”	21572	August 20, 2015	12056-15	March 23, 2015
Hong Kong	“Pharm-Olam”	303317727	September 8, 2015	303317724	March 4, 2015
Hong Kong	“POI”	303317733	September 8, 2015	303317733	March 4, 2015
Hungary	“Pharm-Olam”	1263707	March 4, 2015		
Hungary	“POI”	1257887	March 9, 2015		
India	“Pharm-Olam”	1263707	March 4, 2015		
India	“POI”	1257887	March 9, 2015		
Indonesia	“Pharm-Olam”			J00201501 2761	March 27, 2015
Indonesia	“Pharm-Olam”			J00201501 2763	March 27, 2015
Indonesia	“POI”			J00201501 2765	March 27, 2015
Indonesia	“POI”			J00201501 2766	March 27, 2015
Israel	“Pharm-Olam”	235901	July 11, 2011		February 20, 2011
Israel	“Pharm-Olam”	1263707	March 4, 2015		
Israel	“POI”	1257887	March 9, 2015		

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Italy	“Pharm-Olam”	1263707	March 4, 2015		
Italy	“POI”	1257887	March 9, 2015		
Jordan	“Pharm-Olam”	139665	April 10, 2016	18099	May 13, 2015
Jordan	“Pharm-Olam”	140536	April 10, 2016	18104	May 13, 2015
Jordan	“POI”	140538	April 10, 2016	18101	May 13, 2015
Jordan	“POI”	140537	April 10, 2016	18103	May 13, 2015
Kazakhstan	“Pharm-Olam”	1263707	March 4, 2015		
Kazakhstan	“POI”	1257887	March 9, 2015		
Kuwait	“Pharm-Olam”	148963	May 3, 2015	167951	May 3, 2015
Kuwait	“Pharm-Olam”	136028	May 3, 2015	167952	May 3, 2015
Kuwait	“POI”			169535	June 17, 2015
Kuwait	“POI”	169536	June 17, 2015	169536	June 17, 2015
Latvia	“Pharm-Olam”	1263707	March 4, 2015		
Latvia	“POI”	1257887	March 9, 2015		
Lebanon	“Pharm-Olam”	164971	March 18, 2015	31386	March 12, 2015
Lebanon	“POI”	164989	March 19, 2015	31385	March 12, 2015
Lithuania	“Pharm-Olam”	1263707	March 4, 2015		
Lithuania	“POI”	1257887	March 9, 2015		
Malaysia	“Pharm-Olam”	2015053420	March 9, 2015	2015053420	March 9, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Malaysia	“Pharm-Olam”	20150534418	March 9, 2015	20150534418	March 9, 2015
Malaysia	“POI”		Discontinued pursuing		
Mexico	“Pharm-Olam”	1263707	March 4, 2015		
Mexico	“POI”	1257887	March 9, 2015		
Moldova	“Pharm-Olam”	27738	October 16, 2015	036657	June 16, 2015
Moldova	“POI”	27737	October 16, 2015	036656	June 16, 2015
Myanmar	“Pharm-Olam”	4/6413/2015	May 20, 2018	4/6413/2015	December 6, 2017
Myanmar	“POI”	4/6412/2015	May 20, 2018	4/6412/2015	December 6, 2017
Nicaragua	“Pharm-Olam”	2015111623LM	October 16, 2015	2015-001104	April 6, 2015
Nicaragua	“POI”	2015111622LM	October 16, 2015	2015-001103	April 6, 2015
Panama	“Pharm-Olam”	2015053420	March 5, 2015	238889-01	March 5, 2015
Panama	“POI”	238890-01	September 7, 2015	238890-01	March 5, 2015
Paraguay	“Pharm-Olam”	428989	September 1, 2016	09427/15	March 6, 2015
Paraguay	“Pharm-Olam”	488815	August 24, 2016	09464/15	March 6, 2015
Paraguay	“POI”	428814	August 24, 2016	09428/15	March 6, 2015
Paraguay	“POI”	428990	September 1, 2016	09429/15	March 6, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Peru	"Pharm-Olam"	0609464-2015	May 27, 2015	609464	March 4, 2015
Peru	"Pharm-Olam"	0609465-2015	May 29, 2015	609465	March 4, 2015
Peru	"POI"	0609466-2015	May 26, 2015	609466	March 4, 2015
Peru	"POI"	0609467-2015	May 26, 2015	609467	March 4, 2015
Philippines	"Pharm-Olam"	1263707	March 4, 2015		
Philippines	"POI"	1257887	March 9, 2015		
Poland	"Pharm-Olam"	1263707	March 4, 2015		
Poland	"POI"	1257887	March 9, 2015		
Portugal	"Pharm-Olam"	1263707	March 4, 2015		
Portugal	"POI"	1257887	March 9, 2015		
Puerto Rico	"Pharm-Olam"	211611	March 2, 2016	207591-35-0	March 2, 2015
Puerto Rico	"Pharm-Olam"	211334	March 20, 2015	207591-42-0	March 2, 2015
Puerto Rico	"POI"	208788	March 3, 2015	207598-35-0	March 3, 2015
Puerto Rico	"POI"	208796	March 3, 2015	207598-42-0	March 3, 2015
Romania	"Pharm-Olam"	1263707	March 4, 2015		
Romania	"POI"	1257887	March 9, 2015		
Russian Federation	"Pharm-Olam"	1263707	March 4, 2015		
Russian Federation	"POI"	1257887	March 9, 2015		

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Qatar	"Pharm-Olam"			97311	May 24, 2015
Qatar	"Pharm-Olam"			97313	May 24, 2015
Qatar	"POI"			97312	May 24, 2015
Qatar	"POI"			97314	May 24, 2015
Saudi Arabia	"Pharm-Olam"	1436022210	January 3, 2016	1436022210	August 12, 2015
Saudi Arabia	"Pharm-Olam"	1436022211	January 3, 2016	1436022210	August 12, 2015
Saudi Arabia	"POI"	1436022587	January 6, 2016	1436022587	August 18, 2015
Saudi Arabia	"POI"	1436022588	January 6, 2016	1436022588	August 18, 2015
Serbia	"Pharm-Olam"	1263707	March 4, 2015		
Serbia	"POI"	1257887	March 9, 2015		
Singapore	"Pharm-Olam"	1263707	March 4, 2015		
Singapore	"POI"	1257887	March 9, 2015		
Slovakia	"Pharm-Olam"	1263707	March 4, 2015		
Slovakia	"POI"	1257887	March 9, 2015		
Slovenia	"Pharm-Olam"	1263707	March 4, 2015		
Slovenia	"POI"	1257887	March 9, 2015		
South Africa	"Pharm-Olam"			2015/05449	March 3, 2015
South Africa	"Pharm-Olam"			2015/05450	March 3, 2015

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
South Africa	“POI”			2015/05451	March 3, 2015
South Africa	“POI”			2015/05456	March 3, 2015
South Korea	“Pharm-Olam”	1263707	March 4, 2015		
South Korea	“POI”	1257887	March 9, 2015		
Sri Lanka	“Pharm-Olam”			195941	March 6, 2015
Sri Lanka	“Pharm-Olam”			195939	March 6, 2015
Sri Lanka	“POI”			195940	March 6, 2015
Sri Lanka	“POI”			195938	March 6, 2015
Taiwan	“Pharm-Olam”	01768456	May 1, 2016	104011460	March 4, 2015
Taiwan	“POI”	01740173	November 16, 2015	104011461	March 4, 2015
Thailand	“Pharm-Olam”	1621102897	March 24, 2015	979827	March 25, 2015
Thailand	“Pharm-Olam”	161104215	March 25, 2015	979826	March 25, 2015
Thailand	“POI”	161109282	March 25, 2015	979827	March 25, 2015
Thailand	“POI”	161104215	March 25, 2015	979828	March 25, 2015
Spain	“Pharm-Olam”	1263707	March 4, 2015		
Spain	“POI”	1257887	March 9, 2015		
Turkey	“Pharm-Olam”	1263707	March 4, 2015		
Turkey	“POI”	1257887	March 9, 2015		

Country	Mark	Registration No.	Registration Date	Application No.	Application Date
Ukraine	“Pharm-Olam”	1263707	March 4, 2015		
Ukraine	“POI”	1257887	March 9, 2015		
United Arab Emirates	“Pharm-Olam”	233285	May 19, 2015	233285	May 19, 2015
United Arab Emirates	“Pharm-Olam”	233284	May 19, 2015	233284	May 19, 2015
United Arab Emirates	“POI”	233283	May 19, 2015	233283	May 19, 2015
United Arab Emirates	“POI”	233282	May 19, 2015	233282	May 19, 2015
Uruguay	“Pharm-Olam”			463343	March 25, 2015
Uruguay	“POI”			463344	March 25, 2015
Venezuela	“Pharm-Olam”			15-5890	April 24, 2015
Venezuela	“Pharm-Olam”			15-5889	April 24, 2015
Venezuela	“POI”			15-6245	April 29, 2015
Venezuela	“POI”			15-6244	April 29, 2015
Vietnam	“Pharm-Olam”	1263707	March 4, 2015		
Vietnam	“POI”	1257887	March 9, 2015		

Copyrights: None.

Domain Names:

- a) pharm-olam.org
- b) pharm-olam.com
- c) pharmolam.net
- d) pharmolaminternational.com*
- e) quad-rex.com

f) quad-rx.net
g) quadrx.com
h) trivista.net
i) diabetesrespiratorystudy.com
j) poi-it.com
k) mbquest.net
l) poi-domaincache.com
m) pharm-olarn.com
n) mb-quest.com
o) mb-quest.net
p) med-olam.net
q) med-olam.com
r) med-olam.us
s) pharm-olam.mobi
t) poi-survey.com
u) pharm-olma.net
v) pharm-olma.com
w) pharm-olamsucks.net
x) pharm-olamsucks.org
y) pharm-olamsucks.com
z) pharm-olam.info
aa) pharm-0lam.com
bb) pharm-olarrn.com
cc) pharrn-olarrn.com
dd) pharrn-olam.com
ee) pharm-ollam.com
ff) pharn-olam.com
gg) pharm-oiam.com
hh) pharm-olaminternational.net
ii) pharm-olam.net
jj) pharm-olaminternational.com
kk) magenpartners.net
ll) pharmolam.com
mm) pharmolamgroup.biz
nn) pharmolamgroup.net
oo) pharmolaminternational.net
pp) quadrx.biz
qq) quad-rx.biz
rr) quad-rer.biz
ss) pharmolamgroup.com
tt) pharmolam.biz
uu) pharm-olaminternational.biz
vv) pharm-olam.biz
ww) pharm-olam-international.biz
xx) mb-quest.biz
yy) magenpartners.biz
zz) pharm-olam.us
aaa) mbquest.biz
bbb) magen-partners.biz

ccc) brecoresearch.biz
ddd) tri-vista.biz
eee) breco.biz
fff) biovista.biz
ggg) bio-vista.biz
hhh) medolam.biz
iii) magenpartners.com
jjj) medolam.net